文献速递银屑病与炎症性皮肤病

西班牙BIOBADADERM登记中九种银屑病系统药物的长期安全性队列研究

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
PubMed 文献 · J Am Acad Dermatol · 2020-03-22

该研究基于西班牙BIOBADADERM登记的前瞻性队列,纳入2845例中重度银屑病患者(8954个治疗周期,9642患者年),以甲氨蝶呤为参照,比较阿维A、阿达木单抗、阿普米司特、环孢素、依那西普、英夫利西单抗、甲氨蝶呤、司库奇尤单抗和乌司奴单抗的不良事件发生率比(IRR)及校正IRR。乌司奴单抗和司库奇尤单抗在多个系统器官类别中不良事件发生率最低(IRR<1),而环孢素和英夫利西单抗最高(IRR≥5)。

要点

  • 乌司奴单抗和司库奇尤单抗在多个系统器官类别中不良事件发生率显著低于甲氨蝶呤(IRR<1)。
  • 环孢素和英夫利西单抗不良事件发生率比最高(IRR≥5)。
  • 该真实世界比较安全性数据可辅助临床在九种系统药物间进行选择。

核心结论

  • 乌司奴单抗和司库奇尤单抗在多个系统器官类别中不良事件发生率最低(IRR<1),环孢素和英夫利西单抗最高(IRR≥5)。

研究设计与样本

  • 前瞻性队列研究,使用西班牙BIOBADADERM登记,纳入2845例中重度银屑病患者(8954个治疗周期;9642患者年),以甲氨蝶呤为参照计算IRR及校正IRR(含倾向评分)。

主要发现

  • 乌司奴单抗和司库奇尤单抗在多个系统器官类别中不良事件发生率显著降低(IRR<1)。
  • 环孢素和英夫利西单抗不良事件发生率比最高(IRR≥5)。

临床怎么用

  • 在真实临床实践中,可参考不同系统药物的比较安全性数据,在九种药物间进行个体化选择。

局限性

  • 观察性研究,药物分配非随机化,存在易感者耗竭,且未登记处方剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. OBJECTIVE: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. METHODS: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. RESULTS: Our study included 2845 patients (8954 treatment cycles; 9642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ classes, with a statistically significant decreased rate ratio (IRR of <1), whereas cyclosporine and infliximab had the highest, with an increased rate ratio (IRR of ≥5). LIMITATIONS: Observational study, drug allocation not randomized, depletion of susceptibles, and prescribed doses not registered. CONCLUSION: Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Daudén E, Carretero G, Rivera R, et al. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. J Am Acad Dermatol. 2020. PMID: 32213306. doi:10.1016/j.jaad.2020.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。